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Background: Ruxolitinib, a Janus kinase 1 and 2 inhibitor, demonstrated improvements in spleen volume,
symptoms, and survival over placebo and best available therapy in intermediate-2 or high-risk myelofibrosis patients
with baseline platelet counts ≥100 × 109/L in phase III studies. The most common adverse events were
dose-dependent anemia and thrombocytopenia, which were anticipated because thrombopoietin and
erythropoietin signal through JAK2. These events were manageable, rarely leading to treatment discontinuation.
Because approximately one-quarter of MF patients have platelet counts <100 × 109/L consequent to their disease,
ruxolitinib was evaluated in this subset of patients using lower initial doses. Interim results of a phase II study of
ruxolitinib in myelofibrosis patients with baseline platelet counts of 50-100 × 109/L are reported.
Methods: Ruxolitinib was initiated at a dose of 5 mg twice daily (BID), and doses could be increased by 5 mg once
daily every 4 weeks to 10 mg BID if platelet counts remained adequate. Additional dosage increases required
evidence of suboptimal efficacy. Assessments included measurement of spleen volume by MRI, MF symptoms by
MF Symptom Assessment Form v2.0 Total Symptom Score [TSS]), Patient Global Impression of Change (PGIC);
EORTC QLQ-C30, and safety/tolerability.
Results: By week 24, 62% of patients achieved stable doses ≥10 mg BID. Median reductions in spleen volume and TSS
were 24.2% and 43.8%, respectively. Thrombocytopenia necessitating dose reductions and dose interruptions occurred
in 12 and 8 patients, respectively, and occurred mainly in patients with baseline platelet counts ≤75 × 109/L. Seven
patients experienced platelet count increases ≥15 × 109/L. Mean hemoglobin levels remained stable over the treatment
period. Two patients discontinued for adverse events: 1 for grade 4 retroperitoneal hemorrhage secondary to multiple
and suspected pre-existing renal artery aneurysms and 1 for grade 4 thrombocytopenia.
Conclusions: Results suggest that a low starting dose of ruxolitinib with escalation to 10 mg BID may be appropriate
in myelofibrosis patients with low platelet counts.
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Myelofibrosis (MF) is a Philadelphia chromosome-negative
myeloproliferative neoplasm (MPN), including primary
MF (PMF), post-polycythemia vera MF (PPV-MF) and
post-essential thrombocythemia MF (PET-MF) [1]. MF is
characterized by bone marrow fibrosis and extramedullary
hematopoiesis, primarily in the spleen [2]. The clinical
course of MF is varied, but it is associated with substantial
morbidity and early mortality. Patients often develop de-
bilitating constitutional and splenomegaly-related symp-
toms, which severely reduce quality of life (QoL) [1].
Hematologic manifestations include anemia, neutropenia
and thrombocytopenia, with eventual progression to bone
marrow failure and increased risk of acute myelogenous
leukemia [1].
Dysregulated Janus kinase (JAK)-signal transducer and
activator of transcription (STAT) signaling, as well as muta-
tions in JAK2, are common in Philadelphia chromosome-
negative MPNs [3]. The JAK-STAT pathway is essential
for the regulation of myeloproliferation and immune
response [4]. Ruxolitinib is a potent, orally administered
inhibitor of JAK1 and JAK2 [5]. Ruxolitinib treatment re-
duced spleen volume and improved MF-related symptoms
and QoL measures in patients with intermediate-2 or
high-risk MF, as defined by the International Prognostic
Scoring System (IPSS) [6], in the phase III COntrolled
MyeloFibrosis Study with ORal JAK Inhibitor Treatment
(COMFORT)-I and COMFORT-II studies [7,8]. Ruxoliti-
nib was also associated with a survival advantage over pla-
cebo and best available therapy [7,9,10]. The most
commonly observed adverse events (AEs) in the phase III
trials were dose-dependent anemia and thrombocytopenia,
which were anticipated as thrombopoietin and erythropoi-
etin signal through JAK2 [11]. These events were manage-
able with dose interruption and titration, very rarely
leading to treatment discontinuation. In addition to the
efficacy and safety data from the COMFORT studies,
exploratory analyses of bone marrow fibrosis samples
from a phase I/II study [12] suggest that long-term
treatment with ruxolitinib may delay the natural pro-
gression of bone marrow fibrosis seen in patients with
myelofibrosis [13].
Among patients with PMF, approximately one-quarter
have platelet counts <100 × 109/L as a consequence of
the disease [14-16]. Patients enrolled in the COMFORT
trials, however, were required to have a baseline platelet
count of ≥100 × 109/L and received ruxolitinib starting
doses of 15 or 20 mg twice daily. Therefore, a phase II study
was conducted to assess the efficacy and safety of rux-
olitinib when initiated at a lower starting dose (5 mg
twice daily) with subsequent dose escalation in patients
with MF who had baseline platelet counts of 50–100 ×
109/L. We present an interim analysis of 50 patients en-
rolled in this study.Methods
Patients
Men or women ≥18 years of age with PMF, PPV-MF or
PET-MF [17,18] were enrolled. Patients were required to
have active symptoms, defined as one symptom score ≥5
or two symptom scores ≥3 at screening on the modified
Myelofibrosis Symptom Assessment Form (MFSAF) ver-
sion 2.0, which assessed night sweats, itching, abdominal
discomfort, pain under ribs on left side, early satiety,
bone/muscle pain and inactivity on a scale from 0 (ab-
sent) to 10 (worst imaginable) [7]. Eligible patients had
platelet counts of 50–100 × 109/L at screening and/or
baseline visits, hemoglobin concentrations ≥65 g/L, per-
ipheral blood blast count <5%, Dynamic International
Prognostic Scoring System (DIPSS) [19] score ≥1, life ex-
pectancy 6 months or greater, Eastern Cooperative On-
cology Group performance status ≤3, and were not
being considered for stem cell transplant. Splenomegaly
of any degree was not required for enrollment. Patients
discontinued all MF treatments at least 14 days before
the first dose of study medication.
Patients were excluded if they had well-controlled MF
on current therapy; inadequate bone marrow reserve as
demonstrated by absolute neutrophil count (ANC) <1.0 ×
109/L at screening visit, confirmed platelet count <50 ×
109/L, known history of platelet counts <25 × 109/L in the
absence of cytoreductive therapy or platelet transfusion(s)
or ANC levels <500/μL in the 30 days before screening
visit; major bleeding within 12 months of screening, re-
quiring transfusion or resulting in hemoglobin decrease
≥30 g/L; history of esophageal/gastric varices or intracra-
nial bleeding; or an international normalized ratio >1.5
times the upper limit of normal (ULN) or a partial throm-
boplastin time >1.5 times the ULN. Additional exclusion
criteria were inadequate hepatic or renal function at
screening and baseline visits as demonstrated by direct
bilirubin ≥2 times the laboratory ULN, alanine amino-
transferase >2.5 times the laboratory ULN, or creatinine
>2.0 mg/dL; active bacterial, fungal, parasitic or viral infec-
tion; invasive malignancy in the previous 2 years; recent
severe or unstable cardiac disease; splenic irradiation
within 6 months; current therapy with moderate or potent
cytochrome P450 3A4 inhibition; or previous JAK inhibi-
tor therapy.
Study design and treatment
This phase II, multicenter, open-label study is being con-
ducted in the United States (ClinicalTrials.gov identifier:
NCT01348490; study INCB018424-258). After a screen-
ing period of up to 21 days, eligible patients entered a
7-day baseline assessment phase followed by a 24-week
treatment phase.
Ruxolitinib therapy was initiated at 5 mg twice a day.
Optional dose increases were permitted beginning at
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to a dose of 10 mg twice daily if the following criteria
were met: platelet counts remained ≥40 × 109/L since
the last scheduled study visit; the decline in platelet
count, if decreased since the last study visit, was ≤20%;
ANC was >1.0 × 109/L since the last scheduled visit; no
dose reductions or interruptions for safety occurred dur-
ing the preceding 4-week interval; and any grade ≥2
hemorrhage was resolved. Dose increases beyond 10 mg
twice daily, but not exceeding 15 mg twice daily, were
permitted in patients who met these dose escalation criteria
and, in addition, had inadequate response, defined as a
Patient Global Impression of Change (PGIC) score of 3
(“minimally improved”) to 7 (“very much worse”). Dose in-
creases after week 16 were not allowed unless the increase
was related to recovery from a prior dose reduction or
hold. Protocol-mandatory dose reductions were required
for platelet counts ≥25 × 109/L to <35 × 109/L, and dose in-
terruptions were required for platelet counts <25 × 109/L,
ANC <0.5 × 109/L or grade ≥2 active hemorrhage. Dosing
could be restarted or re-escalated when platelet counts re-
covered to ≥35 × 109/L.
The study was approved by institutional review boards
of participating institutions and was conducted in ac-
cordance with the Declaration of Helsinki, as outlined
in the International Conference on Harmonization
Guideline for Good Clinical Practice, and applicable
regulatory requirements. All patients provided informed
written consent.
Endpoints and assessments
For this interim analysis, the following protocol-
planned endpoints were evaluated: percentage change
from baseline in spleen volume at week 24, as measured
by magnetic resonance imaging (MRI) or computed
tomography scan in patients who were not candidates
for MRI or MRI was not available, and percentage
change from baseline in Total Symptom Score (TSS) at
week 24, as measured by the modified MFSAF version
2.0. MRI or CT scans were measured at baseline and at
week 24 and read by a central reader blinded to initial
treatment assignment. Spleen volume was calculated
using a planimetry approach and validated software. Pa-
tients provided daily ratings for the severity of the fol-
lowing MF symptoms using the MFSAF version 2.0
electronic diary: night sweats, itching, abdominal dis-
comfort, pain under ribs on left side, early satiety, bone/
muscle pain and inactivity. Ratings for individual symp-
tom severity ranged from 0 (absent) to 10 (worst im-
aginable). TSS is the sum of all individual symptoms
with the exception of inactivity. Baseline TSS was the
average of the daily scores for 7 days before initiation of
study drug; week 24 TSS was the average of scores for
the 28 days before the week 24 visit [7].Additional protocol-planned endpoints in this interim
analysis included the proportion of patients with a ≥35%
reduction in spleen volume from baseline at week 24,
the proportion of patients with a ≥10% reduction in
spleen volume from baseline at week 24, the proportion
of patients with a ≥50% improvement in TSS from base-
line at week 24 and the percentage change in spleen
length at each study visit. Spleen length below the left
costal margin was measured by palpation at baseline and
every 4 weeks. Exploratory endpoints included change
from baseline in PGIC, assessed every 4 weeks, and the
European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire-Core 30 (EORTC
QLQ-C30), which was assessed at baseline and weeks 4,
12 and 24.
AEs were routinely monitored in all patients receiving
at least one dose of ruxolitinib. All AEs were graded ac-
cording to the National Cancer Institute’s Common Ter-
minology Criteria for Adverse Events version 4.03.
Analysis populations
As this is an ongoing study, not all patients were en-
rolled in the study for sufficient time to reach the week
24 visit. Therefore, changes from baseline in spleen vol-
ume, spleen length and TSS were based on patients with
available data at week 24. Dose distribution and the re-
sponder analyses (proportion of patients achieving ≥35%
reduction in spleen volume, ≥10% reduction in spleen
volume or ≥50% reduction in TSS from baseline at week
24) were based on an intent-to-treat (ITT) population of
patients who enrolled in the study at least 24 weeks be-
fore the data cutoff. This included patients who either
completed the week 24 visit or discontinued from the
study but would have reached the week 24 visit had they
not discontinued from the study. For the dose distribu-
tion at week 24, patients with missing data were ex-
cluded from the analysis. For the responder analyses,
patients who discontinued before week 24 and patients
with missing values at week 24 were considered nonre-
sponders; patients with missing baseline values were ex-
cluded. Safety analyses were based on all patients who
received at least one dose of study drug. Additional file 1:
Table S1 provides a detailed explanation of the number of
evaluable patients for the dosing, efficacy (spleen volume,
spleen length, and TSS) and safety analyses reported for
this study.
Results
Patient characteristics and disposition
At the time of this interim analysis, a total of 50 patients
had enrolled in this ongoing study. Baseline demograph-
ics and disease characteristics of the study population
are shown in Table 1. Overall, the mean age was 69 years,
62% of patients had PMF, 62% were classified as
Table 1 Patient demographics and disease characteristics
at baseline
Parameter Value (N = 50)






















History of transfusion in 12 weeks before baseline,% 40.0
Previous HU use,% 44.0
Mean platelet count (SD), × 109/L 72.1 (21.9)
Mean hemoglobin (SD), g/L 97.3 (15.7)
Mean WBC (SD), × 109/L 19.6 (20.2)
Mean TSS (SD) 19.4 (11.8)
Mean spleen length (SD), cm 13.4 (7.2)
Mean spleen volume (SD), cm3 2387.3 (1527.3)
Samples will be analyzed for JAK2V617F status at the end of study.
DIPSS, Dynamic International Prognostic Scoring System; ECOG, Eastern
Cooperative Oncology Group; HU, hydroxyurea; JAK, Janus kinase; PET-MF,
post-essential thrombocythemia myelofibrosis; PMF, primary myelofibrosis;
PPV-MF, post-polycythemia vera myelofibrosis; SD, standard deviation; TSS,
Total Symptom Score; WBC, white blood cell.
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count was 72 × 109/L. Of the 50 enrolled patients, 33
completed the week 24 visit, 8 discontinued before week
24 and 9 remained on study and have not yet completed
their week 24 visit. Of the eight patients who discontin-
ued, all were recruited at least 24 weeks before the data
cutoff and were included in the ITT analyses of re-
sponse. Primary reasons for discontinuation included
AEs, withdrawal of consent and disease progression (n =
2 each), as well as death and other (n = 1 each).Dosing and efficacy
Of the 41 patients who were evaluable for dosing, the
median duration of exposure was 24.1 weeks. Dosing in-
formation was available for 37 patients at week 24. Most
patients (23/37; 62%) were titrated to a ruxolitinib twice-
daily dose of 10 mg or higher by week 24; 54% (20/37)
of patients were receiving the 10 mg twice-daily dose at
this time (Figure 1).
In patients who completed 24 weeks of therapy with
available data (n = 30), clinically meaningful reductions
from baseline in spleen volume and spleen length were
observed at week 24. The median percentage change from
baseline in spleen volume was –24.2% (range –55.8% to
38.5%). The majority of patients experienced some de-
crease in their spleen volume (Figure 2A). When evalu-
ated by titrated dose (average dose over the last 4 weeks
of the study, up to week 24), median percentage changes
from baseline in spleen volume at week 24 were –16.7%
for 5 mg once or twice daily (n = 7) and –28.5% for 10 mg
twice daily (n = 20). By week 24, three patients had in-
adequate response and were escalated to doses >10 mg
twice daily; the median percentage change from base-
line in spleen volume in these patients was –6.6%. The
median percentage change from baseline in spleen
length at week 24 in the 30 patients with available data
was –29.7% (range –100.0% to 58.3%). Improvements
in spleen length were observed as early as week 4, and
were maintained throughout the 24-week study period
(Figure 2B). Forty patients were evaluable for the spleen
volume responder analyses (Additional file 1: Table S1).
A ≥35% reduction in spleen volume was experienced by
eight patients (20.0%), and a ≥10% reduction occurred in
21 patients (52.5%). Notably, two patients who were con-
sidered nonresponders in the spleen volume responder
analyses (because of missing MRI data at week 24) experi-
enced clinically meaningful reductions in spleen length
(–40.6% and –43.8%).
Decreases in TSS, indicating improvement in symp-
toms, were also observed in patients who completed
24 weeks of therapy (n = 32). The median percentage
change from baseline in TSS at week 24 was –43.8%
(range –98.6 to 178.6); most patients experienced some
level of improvement in TSS (Figure 2C). Median per-
centage changes from baseline in TSS at week 24 by a
titrated dose were 13.0% for 5 mg once or twice daily
(n = 8) and –63.5% for 10 mg twice daily (n = 21). In the
three patients who had to escalate to doses >10 mg twice
a day because of inadequate response, median percent-
age change from baseline in TSS at week 24 was –33.8%.
As observed with changes in spleen length, symptom im-
provements occurred at week 4 and were maintained
throughout the 24-week study period (Figure 2D). In
addition, median changes from baseline in the following
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Figure 1 Distribution of ruxolitinib daily dose over the 24-week study period. N values represent patients with available dose information
at the time of data analysis. Data shown for each time point represent the dose (in milligrams) that patients were receiving during the previous
4 weeks. BID, twice daily; QD, once daily.
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pain under left ribs (–50.0%), early satiety (–37.7%), night
sweats (–73.0%), itching (–70.5%), bone or muscle pain
(–37.3%) and inactivity (–28.8%). Forty-one patients were
evaluable for the TSS responder analysis (Additional file 1:
Table S1). At week 24, 14 patients (34.1%) experienced
a ≥50% improvement in TSS.
More than one-third of patients reported their symptoms
as “much improved” or “very much improved,” as meas-
ured by the PGIC at week 4, which was before protocol-
allowed dose optimization. By week 8 and continuing
through week 24, more than one-half of the patients re-
ported their symptoms to be at this level of improve-
ment. Patients also reported improvements in QoL
measures at week 24, including Global Health Status/
QoL, as well as functional domains and most symptom
scales of the EORTC QLQ-C30 (Figure 3).
Safety and tolerability
A total of 50 patients received at least one dose of ruxoliti-
nib and were included in the safety analyses. The most
common nonhematologic AEs, regardless of causality,
were diarrhea (28.0%), peripheral edema (26.0%), nausea
(24.0%), abdominal pain (24.0%) and fatigue (22.0%)
(Table 2). Grade 3 or 4 events of diarrhea, nausea, abdom-
inal pain or fatigue each occurred in 4.0% of patients; no
grade 3 or 4 events of peripheral edema were reported.
Reductions in platelet counts to levels <35 and ≥25 ×
109/L required dose reductions per the study protocol
and were experienced by 12 (24.0%) patients. Of these,
nine had a baseline platelet count of ≤75 × 109/L. Eight
(16.0%) patients, seven of whom entered the study with
a platelet count ≤75 × 109/L at baseline, developed grade
4 thrombocytopenia (<25 × 109/L). Of these patients,
one patient with a baseline platelet count of 56 × 109/L
experienced grade 4 thrombocytopenia (platelet count of19 × 109/L) with grade 1 epistaxis after approximately
4 weeks of therapy. The patient had previously experi-
enced grade 1 epistaxis during the screening period that
resolved before the first dose of ruxolitinib. Dosing was
interrupted and the patient received platelet transfu-
sions. The thrombocytopenia did not resolve and the pa-
tient was discontinued from the study.
Events associated with bruising were reported in six
(12.0%) patients, three (6.0%) patients reported ecchy-
mosis and three (6.0%) patients reported contusion. All
events were grade 1 with the exception of one event that
was not graded at the time of the data cutoff. Grade 2
hemorrhage was reported in three (6.0%) patients: (i)
epistaxis (5 mg AM/10 mg PM; event duration 1 day; no
dose interruption); (ii) hematochezia concurrent with di-
verticulitis, abdominal pain and diarrhea (5 mg twice
daily; event duration 18 days; no dose interruption); and
(iii) rectal hemorrhage, resulting from exacerbation of
internal hemorrhoids secondary to chronic constipation
(5 mg twice daily; event duration 2 days; dose interrupted
for 2 days). Before the bleeding events, platelet counts
were >35 × 109/L in each patient; all three remained on
study and no platelet transfusions were required. One pa-
tient with suspected pre-existing renal aneurysms before
study therapy initiation experienced grade 4 retroperito-
neal hemorrhage secondary to multiple renal artery aneu-
rysms, with acute renal failure resulting in discontinuation
from the study. Before the event occurred, the patient’s
platelet count was 71 × 109/L.
Although individual patients may have experienced
platelet count reductions at various times during the
study, the mean percentage change in platelet count for
the study population was generally stable over the
course of the 24-week treatment period (Figure 4A). In-
dividual patients’ changes in platelet counts from base-
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Figure 2 Efficacy results at 24 weeks. (A) Percentage change
from baseline in spleen volume for individual patients at week 24.
(B) Median percentage change from baseline in spleen length over
time. (C) Percentage change from baseline in TSS in individual
patients at week 24. (D) Median percentage change in TSS over
time. Median dose is shown for patients with available dosing
information. TDD, total daily dose; TSS, Total Symptom Score.
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able to maintain adequate platelet counts during the
course of the study. Seven patients had increases in
platelet counts of ≥15 × 109/L from baseline at week 24.
These patients were generally younger, more recently di-
agnosed with MF, at lower risk by DIPSS, more likely to
have PMF and had a lower neutrophil count at baseline
compared with patients who had lesser increases or de-
creases in platelet counts (Additional file 2: Table S2).
Mean hemoglobin concentrations remained stable
throughout the study. This was also observed in patients
who did not receive transfusions (Figure 4C). The mean
hemoglobin concentration in this subset of patients
remained near the baseline level of 109 g/L throughout
the study. Twenty patients required a red blood cell
(RBC) transfusion in the 12 weeks before baseline. These
patients, along with 10 out of 30 patients who did not
require an RBC transfusion in the 12 weeks before base-
line, required RBC transfusions during the treatment
phase of the study.
The two patients who died during the study included a
67-year-old woman who had a fatal exacerbation of
chronic obstructive pulmonary disease and a 68-year-old
man who was reported to have died of natural causes.
Discussion
This interim analysis from an ongoing phase II study sug-
gests that a dosing strategy starting at 5 mg twice a day
with gradual titration based on hematologic parameters
and response can provide clinical benefit in patients with
MF who have platelet counts of 50–100 × 109/L. Reduc-
tions in palpable spleen length and improvements in
symptoms were observed as early as week 4 when most
patients were receiving ruxolitinib doses of 5 mg twice a
day. By week 24, 62% of patients were able to achieve a
stable ruxolitinib dose ≥10 mg twice daily, at which time
the majority of patients had at least a 10% reduction in
spleen volume, a response associated with clinically mean-
ingful improvements in symptoms and QoL [20].
Reductions in spleen volume and improvements in TSS
appeared to be greatest with the titrated dose of 10 mg
twice daily. The small number of patients in the higher-
titrated dose group did not experience the same level of
efficacy; however, lack of response, as indicated by PGIC
scores of 3 (“minimally improved”) to 7 (“very much












































































































































Figure 3 Mean change from baseline to week 24 in quality of
life, functional domains, and symptoms assessed by the EORTC
QLQ-C30. Note: n = 32 for all scales except the Role Functioning and
Cognitive Functioning domain, in which n = 31. EORTC QLQ-C30,
European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire-Core 30; QoL, quality of life; SEM,
standard error of the mean.
Table 2 Adverse events regardless of causality reported
in the safety population (N = 50)
All Grades,
n (%)
Grade 3 or 4,
n (%)
Nonhematologic AEs occurring
in ≥10% of patients
Diarrhea 14 (28.0) 2 (4.0)
Peripheral edema 13 (26.0) 0
Nausea 12 (24.0) 2 (4.0)
Abdominal pain 12 (24.0) 2 (4.0)
Fatigue 11 (22.0) 2 (4.0)
Upper respiratory tract infection 7 (14.0) 0
Vomiting 7 (14.0) 2 (4.0)
Hyperuricemia 6 (12.0) 2 (4.0)
Muscle spasm 6 (12.0) 0
Pyrexia 6 (12.0) 0
Constipation 5 (10.0) 0
Decreased appetite 5 (10.0) 0
Dizziness 5 (10.0) 0
Pleural effusion 5 (10.0) 0
New-onset hematologic AEs
Hemorrhage 8 (16.0)* 1 (2.0)
Bruising (ecchymosis, contusion) 6 (12.0) 0
Laboratory values
Anemia† 29 (64.4) 19 (42.2)‡
Thrombocytopenia 32 (64.0) 28 (56.0)§
*Grade ≥2 hemorrhage reported in four patients (8.0%).
†Denominator for percent calculation includes patients with grade 0, 1, or 2
anemia at baseline.
‡Grade 3 anemia events only are listed. According to CTCAE v4.03, grade 4
anemia requires a clinical assessment of “life-threatening consequences;
urgent intervention indicated” and is not defined by a specific laboratory
cutoff. One patient was reported to have experienced grade 4 anemia as an
adverse event based on investigator clinical assessment.
§Grade 3 thrombocytopenia = 20 patients (40.0%); grade 4 thrombocytopenia = 8
patients (16.0%).
AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events.
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these doses.
In the phase III COMFORT-I study, which enrolled
patients with platelet counts ≥100 × 109/L, the median
reductions in spleen volume and TSS at week 24 were33.0% and 56.2%, respectively (versus 24.2% and 43.8%,
respectively, in this analysis). Although patients in the
COMFORT-I study started at higher doses (15 mg twice
daily for patients with a baseline platelet count 100–200 ×
109/L and 20 mg twice daily for patients with a baseline
platelet count >200 × 109/L), the median titrated twice-
daily doses at week 24 were 10 mg and 20 mg, respectively
[21]. In a post hoc analysis of changes in spleen volume
and TSS in COMFORT-I, patients with a final titrated
dose of 10 mg twice daily achieved slightly lower spleen
volume reductions and similar symptom score improve-
ments as patients receiving higher ending doses [21]. Fur-
ther, in the subgroup of patients in COMFORT-I who had
baseline platelet counts 100–200 × 109/L, the mean reduc-
tion in spleen volume was 23.6% and mean reduction in
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Figure 4 Changes in hematologic parameters. (A) Mean (SEM) platelet counts over time. (B) Changes in individual platelet counts from
baseline to nadir (left panel) and baseline to week 24 (right panel). (C) Mean (SEM) hemoglobin levels over time in patients who did not receive
red blood cell transfusions during the study. SEM, standard error of mean; TDD, total daily dose.
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50–100 × 109/L can initiate ruxolitinib and titrate to
efficacious doses and experience clinically meaningful
outcomes that compare with those seen in patientsfrom COMFORT-I who had baseline platelet counts
of 100–200 × 109/L.
The most common nonhematologic AE was diarrhea,
which was observed at a similar rate (28.0%) to that seen
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ruxolitinib (23.2%) or placebo (21.2%) [7]. As expected,
based on the mechanism of action of ruxolitinib and the
lower starting platelet counts in this patient population,
thrombocytopenia was the most common grade 3 or 4
AE. These events occurred mainly in patients with base-
line platelet counts ≤75 × 109/L and were managed with
dose reductions or dose interruptions. Of interest, seven
patients had increases in platelet counts of ≥15 × 109/L.
The characteristics of this small subgroup suggest that,
patients who are younger and with less advanced MF
may be at a lower risk for developing thrombocytopenia
with ruxolitinib using the dosing scheme in this study.
Mean hemoglobin levels remained relatively stable
over time, with a mean decrease of 0.4 g/L at week 24.
Variation in mean hemoglobin during the current phase
II study was similar to that observed in the placebo arm
of the phase III COMFORT-I study [7]. In contrast, pa-
tients initiating ruxolitinib 15 or 20 mg twice daily in
COMFORT-I experienced initial decreases in mean
hemoglobin of approximately 10 g/L over the first 8 to
12 weeks that subsequently recovered to levels near
baseline. Data from this phase II study are promising for
patients at risk of cytopenias in that it shows use of a
lower starting dose of ruxolitinib with gradual dose es-
calation did not result in a decrease in hemoglobin levels
early in the course of ruxolitinib therapy, which was seen
in COMFORT-I.
Preliminary findings from this study suggest that a
dosing strategy starting with a lower dose of ruxolitinib
with subsequent dose optimization can provide clinically
meaningful reductions in spleen volume and TSS, and is
generally well tolerated in patients with intermediate- or
high-risk MF, as defined by DIPSS, who have platelet
counts of 50–100 × 109/L. Thrombocytopenia was man-
ageable with dose reduction or dose interruption and
mean hemoglobin levels remained stable throughout the
study. Although this study is ongoing, data from this
current analysis will help support individualized ruxoliti-
nib dosing strategies in patients with MF who have
lower platelet counts.
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count <15 × 109/L or decreases in platelet count.
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